Type 2 diabetes

ADA 2021 flags novel T2D drug with impressive glucose and weight control potential

Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, significantly improves glycaemic control and bodyweight in patients with type 2 diabetes. The phase 3 SURPASS-1 RCT, presented at ADA 2021 as the ADA Presidents’ Select Abstract and published in The Lancet, compared once weekly tirzepatide with placebo in 478 patients with diabetes ...

Already a member?

Login to keep reading.

© 2021 the limbic